The aim of this article was to review clinical studies on the use of adipose derived mesenchymal stem cells in the treatment of chronic wounds. A search on PubMed was performed on April 30 th
marrow aspiration. Third, the number of stem cells that can be isolated from adipose tissue is higher than that isolated from bone marrow (5, 6) .
Adipose tissue-derived stem cells express cell markers specifi c to mesenchymal stem cells. Among these are CD34, CD44, CD106, CD117, and STRO-1. But, they do not carry hematopoietic lineage markers (CD45, CD14, CD16, CD61) and endothelial cell markers (CD31, CD144, von Willebrand factor). Adipose-derived mesenchymal stem cells can diff erentiate into osteogenic, condrogenic, myogenic, and adipogenic lineage cells when cultured in vitro (2, 8) .
The reason why mesenchymal stem cells are present in adipose tissue is not clear. There are two theories. First theory proposes that bone marrow-derived circulating stem cells resite to adipose tissue. The similarities between bone marrow-derived and adipose tissue-derived mesenchymal stem cells support this theory. Second theory suggests that stem cells in adipose tissue are in fact pericytes. Pericytes are present in microvessels as a support cell. While they express some of the mesenchymal stem cell markers (CD44, CD73, CD90, CD105), they do not express endothelial and hematopoietic cell markers. Similar to mesencymal stem cells, pericytes attach to the culture dish, proliferate in culture and diff erentiate into bone, cartilage and adipocytes (2) .
Isolation of Stem Cells from Adipose Tissue
Adipose tissue obtained with surgical procedures is diced into small pieces. Following enzymatic digestion with collagenase, stromal vascular fraction is obtained. Stromal vascular fractions contains several cell types including pre-adipocytes, endothelial cells, smooth muscle cells, pericytes, fi broblasts, mesenchymal stem cells, hematopoietic stem cells, endothelial progenitor cells, erythrocytes, T-lymphocytes, B lymphocytes, monocytes, and macrophages (2) . Stromal vascular fraction is also used in clinical application. But the eff ectiveness of this technique is limited due to the low percentage of stem cells in the stromal vascular fraction (9) .
Mesenchymal stem cells are isolated by culturing stromal vascular cells in cell culture. These cells are injected subcutaneously or directly applied over the wounds. It should be noted that intravascular applications of mesenchymal stem cells carry signifi cant risks (10) .
Preclinical Studies
Adipose tissue-derived mesenchymal stem cells can contribute wound healing by diff erentiating into cells that are involved in wound healing or by secreting several growth factors such as vascular endothelial growth factor (VEGF), basic fi broblast growth factor (bFGF), keratinocyte growth factor, platelet-derived growth factor, insulin-like growth factor 1, EGF, stromal cell-derived factor 1.
Altman et al. applied acellular dermal matrix including human adipose-derived stem cells over wounds in atimic mice. They found that stem cells did not enter systemic circulation and were present in wound tissue at 2 weeks. Adipose-derived stem cells increased microvascular network and increased healing rate (11) . Similar results were reported by Nambu et al. in a diabetic wound model in mice. Stem cells isolated from adipose tissue of mice were applied in streptozotocine induced diabetic mice (12) . Wound healing rate increased, and skin biopsies demonstrated increased capillary density after adipose tissue-derived stem cells application.
Kim et al. cultured adipose tissue-derived stem cells with human dermal fi broblasts. They found that adipose tissue derives stem cells increased type I collagen synthesis, Type I and Type III collagen and fi bronectin mRNA levels in fi broblasts (13) .
Ebrahimian et al. demonstrated that adipose-derived stem cells that injected to wound tissue secretes VEGF, incorporate into capillary walls and express endothelial phenotype (14) . They showed increased capillary density and perfusion after stem cell application.
Hong et al. compared the eff ectiveness of bone marrow and adipose tissue-derived stem cells in a rabbit ear wound model (15) . They found that adipose-derived but not bone marrow-derived stem cells increased granulation tissue. Furthermore, they showed that adipose-derived stem cells get fi broblast phenotype after topical application, proliferate in the wound and recruit endothelial cells.
The survival of transplanted stem cells in the wound tissue is critical in the success of these applications. Kim et al. found that low-level laser increases the eff ectiveness of stem cells by decreasing apoptosis in stem cells (16) .
Diabetics compose a signifi cant portion of patients with chronic wounds. Adipose derives stem cells that isolated from diabetic mice have lower proliferation and migration potential (17 
Data Acquisition
A search on PubMed was performed on April 30 th , 2014 to identify the original studies that used adiposederived stem cells for wound healing in a clinical setting. We used the following keywords (''adipose-derived stem cells'' AND ''wound OR ulcer''). 355 articles were found. Non-English language articles (n=21) were excluded. Titles and abstracts of remaining articles were evaluated. Full text of articles deemed to be potentially relevant (n=23) were obtained and reviewed. References of review articles and clinical studies were also skimmed for additional articles. Thirteen articles were identifi ed. However, one of the two papers by Akita et al. was excluded since, both papers reported the same patient (19, 20) .
Clinical Studies
12 articles were included in this review (Table 1) . Adipose-derived stem cells were used in the treatment of chronic radiation injury (19) (20) (21) , chronic wounds in patients with peripheral arterial disease (18, 22, 23) , facial skin necrosis (12, 24, 25) , and complex perianal fi stula (9,26).
Chronic radiation injury
Akita et al. described the fi rst case of treatment of chronic radiation injury with autologous adipose tissuederived cell suspension. An 89 years old woman, who developed a sacral ulcer (5 cm × 10 cm) 40 years after receiving radiotherapy for uterine cancer, underwent liposuction. Out of 250 ml liposuction material, 5 ml of cell rich fraction was obtained, which contained 3.8 × 10 7 cells. Following sharp debridement of the wound bed, the wound was covered with artifi cial dermis, which was soaked by autologous adipose-derived stem cells, together with angiogenic and mitogenic factor of bFGF. The wound was healed at postoperative day 82 (19) . The treatment protocol included FGF in addition to stem cells.
Rigotti et al. injected cell mixture (60-80 cc) derived from autologous lipoaspirates of 20 patients with radiotherapy-induced skin lesions (fi brosis, atrophy, skin retraction, ulcer) (21) . Patients received 1-6 treatments (median: 2 treatments) based on the severity of the symptoms. Patients were followed between 18 and 33 months. They observed improvement in LENT-SOMA scores in 19 (95%) patients. Ulcer was present in 8 patients and wound healing was achieved in all of them. Post treatment skin biopsies revealed new blood vessel formation.
Diabetic foot ulcers
Han and co-workers used cells isolated from lipoaspirates in the treatment of diabetic foot ulcers (27) . 54 patients with non-healing ulcers despite 6 weeks of standard treatment were randomized into control (n=26) and treatment (n=28) groups. Abdominal fat tissue obtained by liposuction was digested with collagenase and fi ltered to prepare a cell mixture. This cell mixture was mixed with fi brinogen and thrombin and applied over the wounds. 4 × 10 6 -8 × 10
6 cells were applied. Patients in the control group received fi brinogen and thrombin without cells. Two patients in the treatment group were excluded due to development of infection. After 8 weeks, while complete healing was observed in all patients (100%) in the treatment group, only 16 (%62) patients in the control group showed complete healing. Complete healing time was 33.8±11.6 days in the treatment group and 42.1 ± 9.5 days in the control group. The authors reported that they did not observe any complication related to the application of cells isolated from lipoaspirate on wounds.
Lee et al. injected autologous adipose-derived stem cells in gastrocnemius muscle of 15 patients with peripheral arterial disease (18) . Of these patients, 3 had diabetes mellitus (18) . Details of this study will be given in the following section on peripheral arterial disease. Two patients had non-healing ulcer, and complete healing was achieved in both of them. The third patient had necrosis on his foot. The necrosis did not improve with stem cell treatment, and he eventually underwent minor amputation. New collateral development was observed in 2 (66.7%) patients. Lee et al. also found that proliferation potential of adipose-derived stem cells isolated from diabetic patients was lower than non-diabetic controls.
Chronic wounds in patients with peripheral arterial disease
Peripheral arterial disease is one of the leading causes of chronic ulcers of lower extremity. Lee (18) . Adverse events included mild fever (n=1), headache (n=1), fl u-like symptoms (n=1), and pain at the injection sites (n=2). Marino et al. used stem cells extracted from autologous fat in the treatment of lower extremity chronic ulcers in 10 patients with peripheral arterial disease. In this study, a commercially available device (Celution system, Cytori Therapeutics, Inc. San Diego, CA) was used to isolate stem cells from adipose tissue. Ten patients received stem cell injections (15 × 10 5 cells/5 ml) at the edges of the ulcer and the remaining ten patients served as controls. Complete healing was achieved in 6 of 10 patients treated with stromal vascular fraction. The authors did not provide any information about the outcome of the patients in the control group.
In a recent Phase I trial, Bura et al. evaluated the feasibility and safety of intramuscular injection of cultured ADSC in patients with critical limb ischemia. Adipose tissue was harvested by liposuction of abdominal fat in 11 patients. All patients had Rutherford III-6 peripheral arterial disease. Two patients were excluded due to contamination of liposuction material, and 2 others were excluded due to amputation before the adiposederived stem cell injection. In remaining 7 patients, after 2 weeks of cell culture, stromal vascular fraction (10 8 cells) was injected into gastrocnemius muscles and anterior compartment of ischemic leg. Injections were made at 15 sites in each muscle using a standard grid. Trans-cutaneous partial oxygen pressure increased in 5 patients and reduced in 1 patient. Three patients (43%) underwent major amputation. Lower extremity ulcers tended to improve in patients who did not undergo amputation. The authors reported no adverse event related to adipose derived stem cell treatment.
Facial skin necrosis
Sung et al. used ADSC for the treatment of nasal skin necrosis secondary to fi ller injection in 2 patients. Stromal vascular fraction was prepared from fat tissue obtained by abdominal liposuction. Stromal vascular fraction were both injected into the lesions at the subcutaneous and dermal levels and used for wound coverage. Complete epithelization was achieved 8 and 10 days after injection.
Jo et al. used adipose derived stem cell for the treatment of facial skin defects in 4 patients. The patients had small full-thickness skin defects on the facial area. Three of the wounds were on the nasal tip. Lipoaspirates, which was taken from the patient's inner thigh or abdomen, was used for adipose-derived stem cell isolation. They used both stromal vascular fraction and cultured adipose-derived stem cells up to 6 th passage. Adipose-derived stem cells (5 × 10 5 -1 × 10 6 cells) were injected 2-5 times with 10-20 day intervals between injections. All patients healed in 1 or 11 month after using stem cell local injections and topical application.
Complex perianal fi stula
Garcia-Olmo et al. compared the eff ectiveness of fi brin glue with and without adipose-derived stem cells in patients with complex perianal fi stula (26) . Adiposederived stem cells were expanded in cell culture after isolation from lipoaspirate. Adipose-derived stem cells (20 × 10 6 ) were injected into fi stula walls. If the fi stula did not heal at 8 weeks, a second injection of adiposederived stem cells (40 × 10 6 ) was performed. Out of 24 patients receiving stem cell therapy, 17 (71%) showed fi stula healing while only 4 (16%) out of 25 patients treated with fi brin glue healed. Furthermore, they found that the quality-of-life was higher in patients receiving ADSC therapy. However, in a recent Phase III study from the same group, the eff ectiveness of 20 × 10 6 stem cells alone (n=64), stem cells with fi brin glue (n=60) and fibrin glue alone were compared in the treatment of perianal fi stula (28) . Healing rates for each group were 39.1%, 43.3%, and 37.3% at 6 th months, and 57.1%, 52.4%, and 37.3% at 1 year, respectively (16) . There was no statistically signifi cant diff erence between the groups.
In another study, Garcia-Olmo and colleagues compared the eff ectiveness of stromal vascular fraction and expanded adipose-derived stem cells in the treatment of enterocutaneous fi stula in patients with Crohn's disease (9) . They found that while 3 of 4 patients who received adipose-derived stem cells had cure, only 1 of 4 patients who received stromal vascular fraction had cure. This study suggests that expanded adiposederived stem cells are more eff ective than stromal vascular fraction (9) .
Later, the same group investigated the eff ect of allogeneic adipose-derived stem cells in the treatment of complex perianal fi stula in Crohn's disease (29 expanded in culture, and 20 million stem cells were injected into one draining anal fi stula in 24 patients. If the fi stula did not close at week 12, a second injection with 40 × 10 6 cells was made. Patients were followed for 24 weeks. Eight patients were dropped out due to various reasons. Nine of 16 patients (56.3%) who completed the study achieved closure of external opening of the treated fi stula at week 24. Complete fi stula closure was achieved in 6/14 (30%) patients. This is the only study that used allogeneic stem cells.
Conclusion and Future Projections
The number of clinical studies investigating the effectiveness of adipose tissue-derived stem cells is limited. ADSCs were used in the treatment of chronic radiation injury (19) (20) (21) , chronic wounds in patients with peripheral arterial disease (18, 22, 23) , facial skin necrosis (12, 24, 25) , and complex perianal fi stula (9, 26) . There are other areas that ADSC therapy may be useful. Among these are the control of scar formation and burn wound healing. Wound maturation, which mainly is composed of control of scar formation, is an important part of the wound healing process. Scar formation is closely related to the infl ammatory process during the wound healing (30) . It is advocated that ADSCs may reduce scar formation with their antiinfl ammatory and immunosuppressive eff ect (31) . In a pig study, Yun et al. injected ADSCs into scars formed after healing of full-thickness skin defects. This study showed that, usage of ADSC is not only reduced the scar size but also improved the scar color and pliability. In the clinical application, Khouri et al. reported burn scar release with lipofi lling (32) .
Another potential application of stem cells is burn wound healing. There are several experimental studies showing eff ectiveness of stem cells on burn wound healing (33) . The promising preclinical research on animal models has validated that stem cells enhance burn wound healing. Stem cell therapy has been used for burn treatment in limited numbers of clinical studies. Natesan et al. showed that mesenchymal stem cells can be isolated from discarded burned skin, and these cells can be used for wound repair and skin regeneration therapies (34). Rasulov et al. showed that allogeneic bone marrow stem cells increased healing in a patient with extensive third degree burn with 30% TBSA (35) . Autologous cultured keratinocytes bearing epidermal stem cells were showed to cover large surface of the burn wound in the treatment of seven major burn patients (36).
Adipose-derived stem cells have the potential to be used in the treatment of chronic wounds. However, standard methods for isolation, storage, and application of these cells are needed. New materials to transfer these stem cells to injured tissues are also investigated. Future studies should aim to develop methods to track transplanted stem cells in the wounds.
